Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

To Investigate Disparities in Strategies for Low-Risk Prostate Cancer by Facility Type Using the Japan Study Group of Prostate Cancer Database.

International journal of urology : official journal of the Japanese Urological Association·2026
Same author

Current status of primary hyperoxaluria type 1 in Japan.

Urolithiasis·2026
Same author

Impact of Human Development Index Category on Prostate Cancer Characteristics in Asia.

The Prostate·2025
Same author

Patient characteristics, treatment patterns, and survival outcomes in patients with castration-resistant prostate cancer: results from the J-CaP registry.

Japanese journal of clinical oncology·2025
Same author

Primary management of prostate cancer by universal health coverage effective coverage index.

World journal of urology·2025
Same author

Changes in the trends of initial treatment for newly diagnosed prostate cancer in Japan: a nationwide multi-institutional study.

Japanese journal of clinical oncology·2024
Same journal

[A Case of Pulmonary Epithelioid Hemangioendothelioma Associated with Multiple Cancers].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Long-Term Survival in Three Cases with Pulmonary Metastases from Colorectal Cancer Given Low-Dose S-1 Under a Regimen Combining a Carbohydrate-Restricted Ketogenic Diet, Metformin, Vitamin D, Eicosapentaenoic Acid, and Other Complementary Therapies].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Preventive Effect of Saline Eye Wash for Eye Symptoms Due to High-Dose and Intermediate-Dose Cytarabine Therapy].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Examination of Factors Affecting the Efficacy of Naldemedine Tosilate Tablets for Opioid-Induced Constipation].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Recent Advances in the Treatment of HER2-Altered Solid Tumors].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[BRAF-Mutant Solid Tumor].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
See all related articles

Related Experiment Video

Updated: Oct 12, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K

[Current Clinical Practice Pattern for Castration-Resistant Prostate Cancer(CRPC)in Japan].

Mizuki Onozawa1, Shiro Hinotsu, Hideyuki Akaza

  • 1Dept. of Urology, International University of Health and Welfare, Narita Hospital.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|November 19, 2021
PubMed
Summary
This summary is machine-generated.

This study analyzed castration-resistant prostate cancer (CRPC) treatments in Japan, finding that while novel agents are increasingly used, conventional agents remain relevant. Survival rates indicate a continued role for established treatments in clinical practice.

More Related Videos

Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

46.3K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

8.1K

Related Experiment Videos

Last Updated: Oct 12, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K
Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

46.3K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

8.1K

Area of Science:

  • Oncology
  • Urology
  • Pharmacology

Background:

  • Castration-resistant prostate cancer (CRPC) presents treatment challenges.
  • Understanding real-world clinical use of CRPC agents in Japan is limited.
  • Androgen-deprivation therapy is a standard initial treatment.

Purpose of the Study:

  • To investigate the clinical utilization patterns of various agents for CRPC in Japan.
  • To analyze treatment details and patient prognosis in a real-world setting.
  • To compare the effectiveness of novel versus conventional agents for CRPC.

Main Methods:

  • Retrospective analysis of 484 CRPC patients from a Japanese multicenter database.
  • Inclusion criteria: diagnosed with CRPC during androgen-deprivation therapy.
  • Data collected: treatment details, continuation rates, and overall survival.

Main Results:

  • Luteinizing hormone-releasing hormone (LH-RH) agonists/antagonists were continued in nearly all CRPC cases.
  • First-line non-castration agents for CRPC: 76.5% novel agents (approved post-2010), 23.5% conventional agents.
  • 1.5-year overall survival from CRPC diagnosis: 63.7% (novel agents: 58.8%, conventional agents: 90.0%).

Conclusions:

  • Conventional agents continue to play a significant role in CRPC management in Japan.
  • Novel agents show promise but require further evaluation in real-world settings.
  • Treatment patterns suggest a mixed approach utilizing both novel and conventional therapies for CRPC.